CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced its participation in two sessions at the 2009 BIO International Convention taking place May 18-21, 2009 at the Georgia World Congress Center in Atlanta, GA.
